Acute effects of N-terminal progastrin fragments on gastric acid secretion in man by Goetze, Jens P et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Acute effects of N-terminal progastrin fragments on gastric acid secretion in man
Goetze, Jens P; Hansen, Carsten P; Rehfeld, Jens F
Published in:
Physiological Reports
DOI:
10.14814/phy2.13164
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Goetze, J. P., Hansen, C. P., & Rehfeld, J. F. (2017). Acute effects of N-terminal progastrin fragments on gastric
acid secretion in man. Physiological Reports, 5(5), [e13164]. https://doi.org/10.14814/phy2.13164
Download date: 03. Feb. 2020
ORIGINAL RESEARCH
Acute effects of N-terminal progastrin fragments on gastric
acid secretion in man
Jens P. Goetze1, Carsten P. Hansen2 & Jens F. Rehfeld1
1 Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
2 Department of Gastrointestinal Surgery, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Keywords
Acid secretion, inhibition, N-terminal,
progastrin, regulation.
Correspondence
Jens P. Goetze, Department of Clinical
Biochemistry (KB3014), Rigshospitalet,
9 Blegdamsvej, DK-2100 Copenhagen,
Denmark.
Tel: +45-3545-2202
Fax: +45-3545-2880
E-mail: JPG@dadlnet.dk
Funding information
The study was supported by grants from the
Danish Cancer Foundation and the P.A.
Messerschmidt Foundation.
Received: 15 November 2016; Revised: 21
January 2017; Accepted: 23 January 2017
doi: 10.14814/phy2.13164
Physiol Rep, 5 (5), 2017, e13164,
doi: 10.14814/phy2.13164
Abstract
We previously identified an N-terminal fragment of progastrin in human
antrum and plasma, where it circulates in high concentrations. In this study,
we examined the effects of N-terminal progastrin fragments on gastric acid
secretion by infusion in healthy individuals. Increasing doses of progastrin
fragment 1-35 were infused intravenously during constant gastric acid stimula-
tion by gastrin-17. In addition, the effects of progastrin fragment 1-35, frag-
ment 6-35, and fragment 1-19 on gastrin-17 stimulated acid secretion were
tested. The gastrin-17 stimulated acid secretion decreased 30% after adminis-
tration of a high dose of progastrin fragment 1-35 (P < 0.05). In extension, a
1-h infusion of fragment 1-35 also decreased gastric acid output. In contrast,
fragment 6-35 did not affect acid secretion, and a single infusion of gastrin-17
alone did not reveal fading of gastric acid output during the time course of
the experiments. The results show that N-terminal fragments of progastrin
may acutely affect gastrin-stimulated gastric acid secretion in vivo. Structure-
function analysis suggests that the N-terminal pentapeptide of progastrin is
required for the effect.
Introduction
The gastrointestinal hormone gastrin is the major regu-
lator of gastric acid secretion (Gregory and Tracy
1964). Gastrin is synthesized in antroduodenal G-cells
by elaborate processing of progastrin into a number of
acid stimulatory peptides (Gregory 1974), of which gas-
trin-34 and gastrin-17 predominate in circulation
(Yalow and Berson 1970; Rehfeld 1972). Common for
all acid stimulatory gastrins is the C-terminal active
site, Trp-Met-Asp-Phe-NH2 (Morley et al. 1965; Gregory
1974).
In addition to acid stimulatory gastrins, complementary
progastrin-derived fragments are also released from G-
cells. N-terminal progastrin fragments have been
identified in gastrinoma tissue (Reeve et al. 1984; Des-
mond et al. 1987; Huebner et al. 1991) and non-neoplas-
tic human antral tissue (Rehfeld and Johnsen 1994).
Besides intact progastrin 1-80, the N-terminal fragments
1-35, 6-35, and 20-36 were identified by mass spectrome-
try, the 1-35 fragment being the most abundant. We have
also shown that N-terminal fragments circulate in almost
30-fold higher concentration than gastrins (286 versus
10 pmol/L) and with a long elimination phase as com-
pared to gastrin-17 (Goetze et al. 2006). Besides gastrins,
dominately gastrin-17 and gastrin 34, and N-terminal
prograstrin fragments, dominately progastrin 1-35 and
prograstrin 1-19, a mixture of other processing-intermedi-
ates, namely glycine-extended gastrins, are circulating;
please see Rehfeld 2014 for a recent review. Apart for
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gastrins, however, no specific receptor has been identified
for any of the processing intermediates.
Comparative studies have disclosed that the C-terminal
pentapeptide of bioactive gastrins and the N-terminal
pentapeptide sequence of progastrin are both fully pre-
served in mammals (Yoo et al. 1982; Boel et al. 1983;
Johnsen and Rehfeld 1993). The evolutionary conserva-
tion, taken together with the occurrence of fragment 1-35
in high concentrations in antral tissue and plasma, raise
the possibility of a biological function of the N-terminal
fragments. In this study, we examined the effects of these
fragments on stimulated gastric acid secretion in healthy
individuals.
Materials and Methods
Peptides
N-terminal fragment 1-35 of human progastrin was cus-
tom synthesized (Kem-En-Tec, Copenhagen, Denmark),
as was fragment 6-35 and fragment 1-19 (Cambridge
Research Biochemicals Ltd). The identity and purity of all
peptides was verified by amino acid analysis (Amino
Quant, Hewlett Packard, Waldron, Germany) and mass
spectrometry (MALDI-TOF, Biflex, Bruker, Bremen, Ger-
many). Synthetic human non-sulfated gastrin-17 was pur-
chased from Sigma Chemical (St. Louis, MO).
Subjects
Healthy individuals of both genders were invited for the
studies and all were free of symptoms and signs of gastric
disease (median age 24, range 22–27 years). No subject
included in the study had immunological signs of prior
or present H. Pylori infection. Written and informed con-
sent was obtained from all the volunteers, and the study
was approved by the local ethics committee for medical
research in Copenhagen (KF 02-185/95) in accordance
with the Helsinki II declaration.
Experimental procedures
The infusion studies were carried out randomly on
separate days.
A) Acid secretion during a constant infusion of
gastrin-17 (n = 6)
After an overnight fast, a nasogastric double-lumen tube
(AN10, Andersen Prod. Inc., NC) was inserted with its
tip in the antrum under fluoroscopic control. The resid-
ual gastric content had been evacuated and then the gas-
tric juice was continuously aspirated and collected by an
intermittent-suction apparatus (Egnell, Sweden) in
15 min intervals. Subjects were positioned in the supine
position throughout the examination. After 1 h, gastric
acid secretion was stimulated for 45 min with a 20 pmol/
kg/h infusion with non-sulfated gastrin-17 (hereafter
mentioned as gastrin-17) using a calibrated pump (Per-
fusor Vll, Braun Melsungen, Melsungen, Germany). After
this period, a 40 pmol/kg/h gastrin-17 infusion was
administered during the remaining time of the examina-
tion. This dose rate was chosen because we have earlier
found it to stimulate gastric acid secretion to approxi-
mately 50% of maximal output. Venous blood samples
were drawn every 15 min from a cubital vein in the arm
not used for infusion. Acid secretion output was evalu-
ated using nonparametric testing for each time point
(15 min) as well as comparison between hours. This strat-
egy was used in all experiments, unless otherwise stated.
B) Acid secretion during an infusion of fragment
1-35 (n = 6)
Blood samples and gastric juice were collected as under
A). The progastrin fragment 1-35 was diluted in isotonic
saline containing 1 g/L of human serum albumin after
sterile filtration. The syringes were weighed before and
after the infusions and the remaining peptide solution
from the infusion was stored at 20°C until radioim-
munoassay. The examination began with a 60 min con-
trol period during which isotonic saline was infused
intravenously at 20 mL/h. The progastrin fragment 1-35
was hereafter infused in three consecutive dose rates of
40, 80, and 300 pmol/kg/h; each period lasting 60 min.
C) Acid secretion during an increasing infusion of
progastrin fragment 1-35 and a constant gastrin-
17 infusion (n = 9)
Gastrin-17 was infused in a constant rate of 40 pmol/kg/h
during the whole experiment. After a control period of
60 min during which acid output reached steady state,
progastrin fragment 1-35 was administered in three con-
secutive dose rates of 40, 80, and 300 pmol/kg/h with
each dose period lasting 60 min.
D) Acid secretion during a sudden 1-h infusion of
progastrin fragment 1-35 fragment and a
constant gastrin-17 infusion (n = 6)
A 1-h basal period was allowed. Acid secretion was then
stimulated for 45 min with a 20 pmol/kg/h gastrin-17 fol-
lowed by a 40 pmol/kg/h dose. After reaching steady state
in acid output (45 min after the 40 pmol/kg/h dose
start), the 400 pmol/kg/h progastrin fragment 1-35 was
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infused for 1 h. Hereafter, only the gastrin-17 infusion
was continued for the remaining time of the experiment.
E) Acid secretion during a sudden 1-h infusion of
progastrin fragment 6-35 and a constant gastrin-
17 infusion (n = 6)
Experimental protocol was as under D). Instead of pro-
gastrin fragment 1-35, the progastrin fragment 6-35 was
infused at a calculated dose rate of 400 pmol/kg/h.
F) Acid secretion during a sudden 1-h infusion of
progastrin fragment 1-19 and a constant gastrin-
17 infusion (n = 6)
Experimental protocol was as under D). Instead of pro-
gastrin fragment 1-35, the progastrin fragment 1-19 was
infused at 300 pmol/kg/h.
A-F) The recovery of gastric juice was determined by
infusion of a marker in the lateral lumen of the tube
(230 kBq 57Co-labeled cobalamin, 1.25 mg cobalamin,
and 1 g human albumin diluted in 1000 mL isotonic sal-
ine, 60 mL/h). The lateral lumen ended 12 cm proximal
to the openings of the central canal. The volume of gas-
tric juice was measured for each 15 min period, and the
concentration of H+ was determined by titration to pH
7.0 with an autotitrator (PMH 26, Radiometer,
Denmark). Blood was collected in chilled tubes contain-
ing 39 lmol di-sodium-EDTA and immediately placed
on ice. Plasma was stored at 20°C until radioim-
munoassay.
Radioimmunoassays
The following antisera were used. Antiserum 94023 was
raised against the N-terminus of human progastrin and
measures the plasma concentrations of N-terminal pro-
gastrin fragments 1-35 and 1-19 as described elsewhere
(Goetze et al. 2006). This antiserum recognizes only the
very N-terminal pentapeptide sequence of human progas-
trin and displays no cross-reactivity to other known pep-
tides. N-terminal progastrin 1-10 extended C-terminally
with a tyrosyl residue was used as standards and tracer
where the tracer peptide was monoiodinated for detec-
tion. For measurement of progastrin fragment 6-35, we
used antiserum 88235, which recognizes the epitope
20-25 of human progastrin and hence binds to the
N-terminus of gastrin-52 (Rehfeld and Johnsen 1994).
Antiserum 88235 does not react with carboxyamidated
gastrin-34, -17 or smaller gastrins. Prior to radioim-
munoassay, plasma samples were treated with trypsin for
30 min at room temperature followed by boiling for
10 min to achieve maximal binding. This procedure
cleaves the 1-35 fragment at the monobasic site at amino
acid 19, thereby maximally exposing the sequence 20-25
epitope in progastrin. Synthetic fragment 20-32 extended
with tyrosine at the C-terminus was used as standard
and the corresponding mono-iodinated peptide was used
as tracer. Finally, antiserum 2604 was used to measure
gastrin-17 (Rehfeld et al. 1972; Stadil and Rehfeld 1973).
This assay specifically binds the C-terminus common for
all acid stimulatory gastrins. Hence, antiserum 2604
binds gastrin-71, -34, and -17 with equimolar potency
and its reactivity with cholecystokinin peptides is negligi-
ble. Synthetic human gastrin-17 was used as standard
and mono-iodinated 125I-gastrin-17 as tracer (Stadil and
Rehfeld 1972).
Chromatography
Plasma samples from subjects in the separate experiments
were pooled at the end of the relevant infusion periods. A
1 mL sample was then applied to a 2000 9 10 mm
Sephadex G-50 Superfine column (Pharmacia, Uppsala,
Sweden) and the column was eluted with a barbital buffer
containing bovine albumin (pH 8.2) at 4°C. Fractions of
2 mL were collected. Void and total volume was deter-
mined by elution of 125I-albumin and 22NaCL, respec-
tively. The column was earlier calibrated with synthetic
progastrin fragments 1-35, 1-19, and 6-35 and extracts of
human antral tissue. All fractions were assayed with the
radioimmunoassay described above.
Calculations and statistical analysis
Correction for nonrecovered gastric juice was made for
every 15 min during the infusion experiments (A-F)
according to the equation: VC = VA 9 Qi/Qa, where VC
is the corrected volume, VA the apparent volume, Qi
the amount of radioactivity (counts per min) infused,
and Qa the amount of aspirated radioactivity. All
results are expressed as means  SEM. Statistical analy-
sis was performed by Friedman’s nonparametric two-
way analysis of variance and P < 0.05 were considered
significant.
Results
Acid secretion increases during infusion of
gastrin-17 (part A, n = 6)
The effective gastrin-17 dose rate was 34  3.9 pmol/kg/h
during the 40 pmol/kg/h infusion. No decrease in the
stimulated acid secretion was detected in the time span of
the study, where the acid secretion had reached steady
state (Fig. 1).
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Acid secretion does not change during
infusion of fragment 1-35 (part B, n = 6)
The effective dose rates as estimated from measurements
of peptide in the infusion lines were 34.0  2.5,
67.3  5.5, and 295  10.4 pmol/kg/h. Mean acid output
was 0.55  0.05 mmol H+/15 min in the control period,
and during the three consecutive dose periods, it was
0.34  0.09, 0.34  0.14, and 0.31  0.19 mmol H+/
15 min. None of these dose periods was significantly dif-
ferent from the control period (data not shown).
Acid secretion decreases during an
increasing infusion of progastrin fragment
1-35 and a constant gastrin-17 infusion
(part C, n = 9)
The effective dose rate of gastrin-17 was
43.3  2.0 pmol/kg/h. The plasma concentration of
gastrin-17 and gastric acid secretion reached a plateau
after 30 min (Fig. 2), with a mean acid output of
5.63  0.73 mmol H+/15 min before the infusion of
progastrin fragment 1-35. The dose rates of progastrin
fragment 1-35 were 33.2  2.7, 66.4  5.3, and
276.8  13.0 pmol/kg/h. Mean acid output during con-
comitant infusion of the two peptides was 4.64  0.83,
5.10  0.62, and 3.28  0.55 mmol H+/15 min (Fig. 2).
Only the mean acid output during the last dose interval
was significantly lower than the acid output during the
control period (P < 0.05) with a 29% decrease in acid
secretion. Mean acid output in the last dose interval was
also significantly lower when compared with the other
dose intervals (P < 0.05).
Acid secretion decreases after a sudden 1-h
infusion of progastrin fragment 1-35
fragment and a constant gastrin-17 infusion
(part D, n = 6)
The constant gastrin-17 dose rate was 45  2.8 pmol/kg/
h and the progastrin fragment 1-35 dose given in the
1-h period was 380  13 pmol/kg/h. A decrease in the
mean acid output was not observed during the 1-h infu-
sion of progastrin fragment 1-35 (Fig. 3). A decrease in
acid output was, however, noted during the last period of
the examination. The plasma concentration of gastrin-17
was constant during the whole infusion.
Acid secretion does not change during a
sudden 1-h infusion of progastrin fragment
6-35 and a constant gastrin-17 infusion
(part E, n = 6)
The administered gastrin-17 dose rate was
49.8  2.2 pmol/kg/h and resulted in a stable plasma
concentration after steady state was reached (Fig. 4). Pro-
gastrin fragment 6-35 was infused in a 416  5.4 pmol/
kg/h rate with no significant change in acid output
detected in the periods including the end period after the
progastrin fragment 6-35 infusion.
Acid secretion during a sudden 1-h infusion
of progastrin fragment 1-19 and a constant
gastrin-17 infusion (part F, n = 6)
The effective gastrin-17 dose rate was 61  6.1 pmol/kg/h
and progastrin fragment 1-19 was infused for 1 h in a
268  28.5 pmol/kg/h dose. A maximal fragment 1-19
plasma concentration of 430.5  89.9 pmol/L was reached
at the end of the infusion (t150, Fig. 5). This concentration
of the 1-19 fragment was half of that of the longer progas-
trin fragment 1-35 in experiment D). Gastric acid secretion
Figure 1. Control infusion of gastrin-17. A singular and constant
infusion of gastrin-17 resulted in a steady state in gastric acid
output during the entire time course of the examination. No fading
in acid secretion was demonstrated. Data are given as
means  SEM.
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was only moderately decreased during the infusion period
(t90-150) with no significant decrease in acid output in the
final period of the experiment.
Chromatography
Elution of plasma samples from the infusion of progastrin
fragment 1-35 and gastrin-17 in experiment C) at the end
(t = 180 min, Fig. 3) revealed only one immunoreactive
peak eluting in the same position as the calibration
Figure 2. Gastric acid output during constant gastrin-17 infusion
and a stepwise increase in progastrin fragment 1-35 infusion dose
as described under C) in the methods section. The first 40 pmol/
kg/h dose of progastrin fragment 1-35 was administered during
the first 60 min, then an 80 mol/kg/h infusion from 60–120 min,
and finally the high 300 pmol/kg/h dose during 120–180 min.
Only mean and SEM values for period – 30 min and forward are
shown. n.s. denotes nonsignificant, and the * represents a
P < 0.05.
Figure 3. Constant gastrin-17 infusion and a sudden 1-h (t90-150)
400 pmol/kg/h infusion of progastrin fragment 1-35 as described
under D) in methods. Only mean and SEM values for period –
30 min and forward are shown. n.s. denotes nonsignificant, and
the * represents a P < 0.05.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2017 | Vol. 5 | Iss. 5 | e13164
Page 5
J. P. Goetze et al. Effect of N-terminal Progastrin Fragments
peptide of N-terminal progastrin fragment 1-35 (KD =
0.58, data not shown). No other peaks were detected, sug-
gesting that the infused peptide was not cleaved to smal-
ler N-terminal fragments during the time course of the
examination.
Discussion
Novel roles of gastrins, including progastrin, are currently
under discussion (Giraud et al. 2016; Rehfeld 2016). This
study suggests that N-terminal progastrin fragments
infused in high doses can acutely inhibit gastrin-stimu-
lated acid secretion in man. The inhibitory effect was,
Figure 4. Constant gastrin-17 infusion and a sudden 1-h (t90-150)
400 pmol/kg/h infusion of the progastrin fragment 6-35
as described under E) in methods. Only mean and SEM values
for period – 30 min and forward are shown. n.s. denotes
nonsignificant, and the * represents a P < 0.05.
Figure 5. Constant gastrin-17 and a sudden 1-h (t90-150)
300 pmol/kg/h infusion of the progastrin fragment 1-19 as
described under F) in methods. Only mean and SEM values for
period – 30 min and forward are shown. n.s. denotes
nonsignificant, and the * represents a P < 0.05.
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however, only observed when the fragments were admin-
istered in high doses and there was no clear dose–re-
sponse relationship. In contrast, the inhibitory effect
could not be achieved with an equimolar dose infusion of
the N-terminally truncated form: progastrin 6-35. The
peptide mediating the effect hence seems to require an
intact N-terminus of progastrin.
Acid stimulatory gastrins are peptides of different chain
length which all have the C-terminal tetrapeptide amide
Trp-Met-Asp-Phe-NH2 as active site (Gregory and Tracy
1964; Morley et al. 1965; Hilsted and Rehfeld 1987). Also,
gastrin peptides extended C-terminally with glycine have
been suggested to exert unique biological effects (Seva
et al. 1994). Glycine-extended gastrins have earlier been
examined for their possible role in gastric acid secretion.
However, we could not detect any effect on acid stimula-
tion using the same setup as the present one – even when
administering the peptide in supraphysiological concen-
trations (Hansen et al. 1996; Hilsted et al. 1988; for
review, see Rehfeld 2014). Other progastrin-derived pep-
tides have also been examined for biological activity
(Wang et al. 1996; Baldwin et al. 2001; Smith et al.
2006). Some of these studies, however, did not evaluate
the biological responses to a specific region of the precur-
sor. One study examined a recombinant N-terminal trun-
cated form of the precursor, that is, progastrin 6-80, thus
excluding the N-terminal sequence 1-5 (Baldwin et al.
2001). As this specific epitope was necessary for effect in
our study, it seems, at present, not straightforward to
combine the biological connotation of the findings. On
the other hand, we cannot rule out that the N-terminus
enhances the effects but still depends on the remaining
peptide structure.
N-terminal progastrins circulate in humans in an
almost 30-fold higher concentration than the C-terminal
gastrins during fasting states (Goetze et al. 2006). In this
study, we also showed that meal stimulation increases
both N-terminal progastrin fragments and amidated gas-
trins with gastrin concentrations reaching a plateau
30 min after stimulation. The concentration of N-term-
inal progastrin fragments, however, remained elevated
throughout the entire time period studied after stimula-
tion. Moreover, we have shown the N-terminal fragments
to be released in a more constitutive manner, rather than
the well-known regulated secretion pattern of the C-term-
inal gastrins (Bundgaard and Rehfeld 2008). This suggests
that a relevant biological situation for the inhibitory effect
may be during the fasting states when gastrin concentra-
tions are low. According to such a theory, the acid inhibi-
tion of N-terminal progastrins during stimulated gastrin
release, for example, during meals, would yield to the
brief C-terminal gastrin stimulation of acid secretion. The
present observed inhibitory effect might therefore have
been studied under suboptimal physiological conditions,
as inhibition of acid secretion was evaluated during a
strong and constant stimulation with gastrin-17. This
could also partly explain the lack of a clear dose–response
relationship. Why the effect is seen after the infusion is
not well explained but may suggest that the effect requires
intracellular changes, as for instance transcriptional regu-
lation, before the effect on acid secretion precipitates. In
extension of this, it should also be noted that any poten-
tial long-term effects are not addressed in this study pro-
tocol. Therefore, studies addressing long-term effects on
cellular number/growth and differentiation needs to be
pursued.
The acid secretory response from the parietal cells to
gastrin is primarily mediated through the histamine-
releasing endocrine-like cells – the ECL cells. The
response to N-terminal progastrin fragments may, on the
other hand, be mediated only through the parietal cell,
and thus the inhibitory effect would not be biologically
amplified in the same manner as for the C-terminal gas-
trins. This fits with the different potencies of N-terminal
progastrins and C-terminal gastrins. Also, the somato-
statin-producing D-cells should be considered as mediator
of the effect. A stimulation of paracrine somatostatin
response would regulate both the histamine release and
the acid secretion during fasting states.
In conclusion, this study suggests that the N-terminal
region of human progastrin can inhibit gastrin acid secre-
tion in man. The inhibitory effect was diminished when
removing the N-terminal pentapeptide sequence, which
indicates that this region is involved in the inhibitory
effect. For now, we suggest that N-terminal prograstrin
fragments may play a role for keeping gastric acid secre-
tion low between meals.
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